Aurora Cannabis Croissance future
Future contrôle des critères 4/6
Aurora Cannabis devrait augmenter ses bénéfices et ses revenus de 121.6% et de 5.5% par an respectivement, tandis que le BPA devrait croître de croître de 85.4% par an.
Informations clés
121.6%
Taux de croissance des bénéfices
85.37%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.3% |
| Taux de croissance des recettes | 5.5% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 12 Jun 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Mise à jour du récit • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Mise à jour du récit • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Mise à jour du récit • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.Mise à jour du récit • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.Mise à jour du récit • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.Mise à jour du récit • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.Mise à jour du récit • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Article d’analyse • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Article d’analyse • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...
Mise à jour du récit • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Article d’analyse • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Article d’analyse • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...Article d’analyse • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
Nouveau récit • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Article d’analyse • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Article d’analyse • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...Article d’analyse • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Article d’analyse • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Article d’analyse • Feb 15
Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 365 | N/A | N/A | N/A | 1 |
| 3/31/2028 | 319 | 8 | 9 | 21 | 5 |
| 3/31/2027 | 293 | -17 | -6 | 0 | 6 |
| 3/31/2026 | 321 | -59 | -36 | -14 | N/A |
| 12/31/2025 | 373 | -84 | -31 | -10 | N/A |
| 9/30/2025 | 367 | -57 | -18 | 2 | N/A |
| 6/30/2025 | 358 | -3 | -1 | 18 | N/A |
| 3/31/2025 | 289 | 27 | 1 | 16 | N/A |
| 12/31/2024 | 320 | 15 | -29 | -9 | N/A |
| 9/30/2024 | 296 | -29 | -61 | -43 | N/A |
| 6/30/2024 | 278 | -30 | -67 | -49 | N/A |
| 3/31/2024 | 270 | -53 | -85 | -69 | N/A |
| 12/31/2023 | 266 | -108 | -91 | -71 | N/A |
| 9/30/2023 | 262 | -153 | -145 | -127 | N/A |
| 6/30/2023 | 248 | -195 | -141 | -127 | N/A |
| 3/31/2023 | 224 | -793 | -163 | -142 | N/A |
| 12/31/2022 | 212 | -1,748 | -181 | -157 | N/A |
| 9/30/2022 | 210 | -1,757 | -152 | -118 | N/A |
| 6/30/2022 | 221 | -1,718 | -142 | -110 | N/A |
| 3/31/2022 | 226 | -1,233 | -98 | -64 | N/A |
| 12/31/2021 | 231 | -381 | -122 | -82 | N/A |
| 9/30/2021 | 238 | -607 | -165 | -124 | N/A |
| 6/30/2021 | 245 | -692 | -264 | -211 | N/A |
| 3/31/2021 | 257 | -2,387 | -357 | -284 | N/A |
| 12/31/2020 | 275 | -2,359 | -430 | -285 | N/A |
| 9/30/2020 | 263 | -3,342 | -614 | -357 | N/A |
| 6/30/2020 | 269 | -3,231 | -691 | -342 | N/A |
| 3/31/2020 | 299 | -1,405 | -778 | -293 | N/A |
| 12/31/2019 | 291 | -1,430 | N/A | -289 | N/A |
| 9/30/2019 | 290 | -385 | N/A | -218 | N/A |
| 6/30/2019 | 246 | -294 | N/A | -192 | N/A |
| 3/31/2019 | 168 | -211 | N/A | -233 | N/A |
| 12/31/2018 | 119 | -72 | N/A | -206 | N/A |
| 9/30/2018 | 77 | 174 | N/A | -146 | N/A |
| 6/30/2018 | 55 | 72 | N/A | -82 | N/A |
| 3/31/2018 | 42 | -13 | N/A | -35 | N/A |
| 12/31/2017 | 31 | 7 | N/A | -16 | N/A |
| 9/30/2017 | 23 | -4 | N/A | -15 | N/A |
| 6/30/2017 | 18 | -13 | N/A | -13 | N/A |
| 3/31/2017 | 13 | -16 | N/A | -17 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -11 | N/A |
| 9/30/2016 | 5 | -10 | N/A | -9 | N/A |
| 6/30/2016 | 1 | -6 | N/A | -7 | N/A |
| 3/31/2016 | 0 | 0 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ACB devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3% ).
Bénéfices vs marché: ACB devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: ACB devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ACB ( 5.5% par an) devrait croître plus rapidement que le marché Canadian ( 4.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ACB ( 5.5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ACB devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/19 11:49 |
| Cours de l'action en fin de journée | 2026/06/19 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Aurora Cannabis Inc. est couverte par 15 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |